Altogether, these findings suggested that inadequate PRL suppression by dopamine agonists might alter metabolic homeostasis, triggering excessive body fat accumulation, insulin resistance and metabolic syndrome, and thus promoting the increase in overall cardiovascular risk. This evidence concerns the gene PRL and metabolic syndrome.